Application of pharmacogenomics to dietary cancer chemoprevention

Auemduan Prawan, Tin Oo Khor, Wenge Li, Ah Ng Tony Kong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Many lines of evidence demonstrate that certain dietary phytochemicals have cancer chemopreventive effects. These dietary phytochemicals or chemo-preventive agents can suppress or block carcinogenesis by 1 enhancing the biotransformation enzymatic activities for efficient elimination of carcinogens or reactive oxidative or nitrosative species (ROS/RNS); 2 suppressing the growth/inflammatory signaling pathways involved in cancer cell proliferation; and 3 modulating phase II detoxifying/antioxidant enzymes, e.g. glutathione S-transferases (GST), NAD(P)H-quinone reductase 1 (NQO1), UDP-glueuronosyltransferases (UGT), and antioxidant enzymes such as gamma-glutamylcysteine synthetase (γ-GCS) and heme oxygenase 1 (HO1). Comparison of gene expression profiles among Nrf2 wild type and Nrf2 knockout mice showed that these genes are induced in an Nrf2-dependent manner in response to phytochemical treatments. The potential roles of different types of polymorphisms or pharmacogenetics in carcinogenesis and prevention/ treatment of some of these genes will be described in this review. Finally, the potential usage of these dietary compounds in combination with conventional cancer chemotherapy will also be considered. The applications of pharmacogenomics to dietary cancer chemopreventive studies will be essential for understanding the cancer protective mechanisms and could lead to individualized drug therapies in the future.

Original languageEnglish (US)
Pages (from-to)198-200
Number of pages3
JournalCurrent Pharmacogenomics
Volume5
Issue number3
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Pharmacogenetics
Chemoprevention
Phytochemicals
Neoplasms
Carcinogenesis
Antioxidants
Glutamate-Cysteine Ligase
NAD(P)H Dehydrogenase (Quinone)
Drug Therapy
Heme Oxygenase-1
Uridine Diphosphate
Enzymes
Biotransformation
Glutathione Transferase
Transcriptome
Knockout Mice
Carcinogens
NAD
Genes
Cell Proliferation

Keywords

  • And gene expression profiles
  • Cancer chemoprevention
  • Dietary phytochemicals
  • Microarray
  • Nrf2
  • Pharmacogenomics
  • Signal transduction

ASJC Scopus subject areas

  • Pharmacology
  • Genetics

Cite this

Application of pharmacogenomics to dietary cancer chemoprevention. / Prawan, Auemduan; Khor, Tin Oo; Li, Wenge; Kong, Ah Ng Tony.

In: Current Pharmacogenomics, Vol. 5, No. 3, 09.2007, p. 198-200.

Research output: Contribution to journalArticle

Prawan, Auemduan ; Khor, Tin Oo ; Li, Wenge ; Kong, Ah Ng Tony. / Application of pharmacogenomics to dietary cancer chemoprevention. In: Current Pharmacogenomics. 2007 ; Vol. 5, No. 3. pp. 198-200.
@article{02fc5b3d28d545c5a4ac34cd128758a0,
title = "Application of pharmacogenomics to dietary cancer chemoprevention",
abstract = "Many lines of evidence demonstrate that certain dietary phytochemicals have cancer chemopreventive effects. These dietary phytochemicals or chemo-preventive agents can suppress or block carcinogenesis by 1 enhancing the biotransformation enzymatic activities for efficient elimination of carcinogens or reactive oxidative or nitrosative species (ROS/RNS); 2 suppressing the growth/inflammatory signaling pathways involved in cancer cell proliferation; and 3 modulating phase II detoxifying/antioxidant enzymes, e.g. glutathione S-transferases (GST), NAD(P)H-quinone reductase 1 (NQO1), UDP-glueuronosyltransferases (UGT), and antioxidant enzymes such as gamma-glutamylcysteine synthetase (γ-GCS) and heme oxygenase 1 (HO1). Comparison of gene expression profiles among Nrf2 wild type and Nrf2 knockout mice showed that these genes are induced in an Nrf2-dependent manner in response to phytochemical treatments. The potential roles of different types of polymorphisms or pharmacogenetics in carcinogenesis and prevention/ treatment of some of these genes will be described in this review. Finally, the potential usage of these dietary compounds in combination with conventional cancer chemotherapy will also be considered. The applications of pharmacogenomics to dietary cancer chemopreventive studies will be essential for understanding the cancer protective mechanisms and could lead to individualized drug therapies in the future.",
keywords = "And gene expression profiles, Cancer chemoprevention, Dietary phytochemicals, Microarray, Nrf2, Pharmacogenomics, Signal transduction",
author = "Auemduan Prawan and Khor, {Tin Oo} and Wenge Li and Kong, {Ah Ng Tony}",
year = "2007",
month = "9",
doi = "10.2174/157016007781669187",
language = "English (US)",
volume = "5",
pages = "198--200",
journal = "Current Pharmacogenomics",
issn = "1570-1603",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Application of pharmacogenomics to dietary cancer chemoprevention

AU - Prawan, Auemduan

AU - Khor, Tin Oo

AU - Li, Wenge

AU - Kong, Ah Ng Tony

PY - 2007/9

Y1 - 2007/9

N2 - Many lines of evidence demonstrate that certain dietary phytochemicals have cancer chemopreventive effects. These dietary phytochemicals or chemo-preventive agents can suppress or block carcinogenesis by 1 enhancing the biotransformation enzymatic activities for efficient elimination of carcinogens or reactive oxidative or nitrosative species (ROS/RNS); 2 suppressing the growth/inflammatory signaling pathways involved in cancer cell proliferation; and 3 modulating phase II detoxifying/antioxidant enzymes, e.g. glutathione S-transferases (GST), NAD(P)H-quinone reductase 1 (NQO1), UDP-glueuronosyltransferases (UGT), and antioxidant enzymes such as gamma-glutamylcysteine synthetase (γ-GCS) and heme oxygenase 1 (HO1). Comparison of gene expression profiles among Nrf2 wild type and Nrf2 knockout mice showed that these genes are induced in an Nrf2-dependent manner in response to phytochemical treatments. The potential roles of different types of polymorphisms or pharmacogenetics in carcinogenesis and prevention/ treatment of some of these genes will be described in this review. Finally, the potential usage of these dietary compounds in combination with conventional cancer chemotherapy will also be considered. The applications of pharmacogenomics to dietary cancer chemopreventive studies will be essential for understanding the cancer protective mechanisms and could lead to individualized drug therapies in the future.

AB - Many lines of evidence demonstrate that certain dietary phytochemicals have cancer chemopreventive effects. These dietary phytochemicals or chemo-preventive agents can suppress or block carcinogenesis by 1 enhancing the biotransformation enzymatic activities for efficient elimination of carcinogens or reactive oxidative or nitrosative species (ROS/RNS); 2 suppressing the growth/inflammatory signaling pathways involved in cancer cell proliferation; and 3 modulating phase II detoxifying/antioxidant enzymes, e.g. glutathione S-transferases (GST), NAD(P)H-quinone reductase 1 (NQO1), UDP-glueuronosyltransferases (UGT), and antioxidant enzymes such as gamma-glutamylcysteine synthetase (γ-GCS) and heme oxygenase 1 (HO1). Comparison of gene expression profiles among Nrf2 wild type and Nrf2 knockout mice showed that these genes are induced in an Nrf2-dependent manner in response to phytochemical treatments. The potential roles of different types of polymorphisms or pharmacogenetics in carcinogenesis and prevention/ treatment of some of these genes will be described in this review. Finally, the potential usage of these dietary compounds in combination with conventional cancer chemotherapy will also be considered. The applications of pharmacogenomics to dietary cancer chemopreventive studies will be essential for understanding the cancer protective mechanisms and could lead to individualized drug therapies in the future.

KW - And gene expression profiles

KW - Cancer chemoprevention

KW - Dietary phytochemicals

KW - Microarray

KW - Nrf2

KW - Pharmacogenomics

KW - Signal transduction

UR - http://www.scopus.com/inward/record.url?scp=34648819542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648819542&partnerID=8YFLogxK

U2 - 10.2174/157016007781669187

DO - 10.2174/157016007781669187

M3 - Article

AN - SCOPUS:34648819542

VL - 5

SP - 198

EP - 200

JO - Current Pharmacogenomics

JF - Current Pharmacogenomics

SN - 1570-1603

IS - 3

ER -